Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

<p>Patient characteristics<a href="#t1n1" target="_blank"><sup>a</sup></a>.</p>

Saved in:

Bibliographic Details
Main Author:	John Powderly (15026168) (author)
Other Authors:	Martina Imbimbo (15118007) (author), Antoine Italiano (15054013) (author), Patricia Martin-Romano (22288066) (author), Meredith McKean (20432950) (author), Teresa Macarulla (15050234) (author), Eduardo Castañón Alvarez (22288069) (author), Benedito A. Carneiro (15925723) (author), Raymond Mager (17316025) (author), Vicky Barnhart (22288072) (author), Steven Eck (22288075) (author), Elina Murtomaki (19849066) (author), Arsène-Bienvenu Loembé (22288078) (author), Yun He (22288081) (author), Zachary A. Cooper (15054236) (author), Eric Tu (22288084) (author), Chunling Fan (22288087) (author), Agnes Boyer Chamard (22288090) (author), Carine Paturel (22288093) (author), Paula G. Fraenkel (22288096) (author), Antoine Hollebecque (15010338) (author)
Published:	2025
Subjects:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Combination Immunotherapy Immunotherapy Oncogenes & Tumor Suppressors PD-1 Phase I Clinical Trials
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items